Meritage Portfolio Management Exelixis, Inc. Transaction History

Meritage Portfolio Management

$1.45 Billion
Q4 2025

A detailed history of Meritage Portfolio Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Meritage Portfolio Management holds 289,279 shares of EXEL stock, worth $12 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares

289,279

Previous 295,426 2.08%

Holding current value

$12 Million

Previous $12.2 Million 1.25%

% of portfolio

0.83%

Previous 0.83%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 27, 2026	SELL	$34.54 - $43.59 $212,317 - $267,947	-6,147 Reduced 2.08%	289,279 $12 Million
Q3 2025 Oct 27, 2025	SELL	$36.22 - $46.25 $2.98 Million - $3.81 Million	-82,301 Reduced 21.79%	295,426 $12.2 Million
Q2 2025 Jul 25, 2025	SELL	$34.13 - $46.26 $734,170 - $995,098	-21,511 Reduced 5.39%	377,727 $16.7 Million
Q1 2025 Apr 28, 2025	SELL	$32.38 - $39.16 $275,586 - $333,290	-8,511 Reduced 2.09%	399,238 $14.7 Million
Q4 2024 Jan 27, 2025	SELL	$25.39 - $36.46 $148,201 - $212,817	-5,837 Reduced 1.41%	407,749 $13.6 Million

Q3 2024 Nov 04, 2024	SELL	$21.96 - $27.6 $10,540 - $13,248	-480 Reduced 0.12%	413,586 $10.7 Million
Q2 2024 Aug 08, 2024	BUY	$20.34 - $23.73 $163,309 - $190,528	8,029 Added 1.98%	414,066 $9.3 Million
Q1 2024 Apr 29, 2024	SELL	$20.17 - $23.93 $335,608 - $398,171	-16,639 Reduced 3.94%	406,037 $9.64 Million
Q4 2023 Feb 02, 2024	BUY	$19.25 - $24.13 $535,438 - $671,175	27,815 Added 7.04%	422,676 $10.1 Million
Q3 2023 Oct 30, 2023	BUY	$19.04 - $22.74 $12,985 - $15,508	682 Added 0.17%	394,861 $8.63 Million
Q2 2023 Jul 31, 2023	SELL	$18.17 - $20.48 $345,538 - $389,468	-19,017 Reduced 4.6%	394,179 $7.53 Million
Q1 2023 Apr 25, 2023	SELL	$16.3 - $19.41 $179,935 - $214,266	-11,039 Reduced 2.6%	413,196 $8.02 Million
Q4 2022 Feb 01, 2023	BUY	$14.96 - $17.39 $3.95 Million - $4.59 Million	264,052 Added 164.84%	424,235 $6.81 Million
Q3 2022 Oct 25, 2022	SELL	$15.68 - $22.27 $4.53 Million - $6.43 Million	-288,953 Reduced 64.34%	160,183 $2.51 Million
Q2 2022 Jul 25, 2022	SELL	$17.44 - $23.16 $418,036 - $555,145	-23,970 Reduced 5.07%	449,136 $9.35 Million
Q1 2022 Apr 25, 2022	BUY	$17.03 - $22.67 $8.06 Million - $10.7 Million	473,106 New	473,106 $10.7 Million

Others Institutions Holding EXEL

# of Institutions

698

Shares Held

258M

Call Options Held

1.5M

Put Options Held

1.71M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

News

Stay updated on Meritage Portfolio Management with notifications on news.

Account

Meritage Portfolio Management Exelixis, Inc. Transaction History